Proteostasis Therapeutics Provides Clinical Enrollment Update
BOSTON, Dec. 20, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated...
Aridis Enrolling CF Patients to Test AR-501 in Chronic Lung Infections
Aridis Pharmaceuticals has enrolled the first healthy participant in its Phase 1/2a clinical trial to evaluate the antibacterial...
Specific Sweat Test Better Detects Kalydeco’s Effects on CFTR Function, Study Suggests
The effects of CFTR modulator therapies such as Kalydeco (ivacaftor) can be more reliably assessed using a test that specifically...
Phase 3 Trial of RDEB Therapy EB-101 to Start in 2019, Abeona Therapeutics Says
Abeona Therapeutics plans to start a Phase 3 trial in 2019 testing the cell therapy candidate EB-101 as a treatment for recessive...
People with Rare Diseases Are Humans, Not Commodities
If you keep up with CF research, you may have seen the news about Phase 3 of the triple combination Vertex therapies. In these results,...
Triple Combo Treatment Improves Lung Function in Patients with Cystic Fibrosis
An investigational triple combination treatment regimen for cystic fibrosis (CF) improved patients’ lung function in 2 phase 3 studies,...